Abstract
This JAMA Forum discusses pending legislation in the US House and Senate and the history of the “firm-based approach” the US Food and Drug Administration (FDA) could use when regulating artificial intelligence (AI) medical devices to augment patient care.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have